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Abstract. Brefeldin A has dramatic, well-documented,
effects on the structural and functional organization of
the Golgi complex. We have examined the effects of
brefeldin A (BFA) on the Golgi-localized synthesis and
addition of chondroitin sulfate glycosaminoglycan car-
bohydrate side chains. BFA caused a dose-dependent
inhibition of chondroitin sulfate glycosaminoglycan
elongation and sulfation onto the core proteins of the
melanoma-associated proteoglycan and the major his-
tocompatibility complex class II-associated invariant
chain. In the presence of BFA, the melanoma proteo-
glycan core protein was retained in the ER but still ac-
quired complex, sialylated, N-linked oligosaccharides,
as measured by digestion with endoglycosidase H and
neuraminidase. The initiation of glycosaminoglycan syn-
xE biosynthesis of glycosaminoglycan (GAG)' car-
bohydrate side chains involves an extensive series of
posttranslational enzymatic reactions that occur dur
ing the intracellular transport of core proteins from the ER
through the Golgi complex. These reactions use specific ini-
tiation, elongation, and sulfation enzymes to modify appro-
priate core proteins and assemble them into mature proteo-
glycan molecules. For chondroitin sulfate (CS) GAGS, the
carbohydrate-protein linkage region is initiated by a xylosyl-
transferase that transfers xylose from UDP-xylose to the hy-
droxyl groups of specific serine residues within a core pro-
tein. Initiationis completed by the addition oftwo galactosyl
and one glucuronosyl residue through the action of galac-
tosyltransferase I, II, and glucuronosyltransferase I, respec-
tively. Once initiated, the repeating disaccharide backbone
ofglucuronosyl andN-acetylgalactosaminyl residues is elon-
gated by specific glucuronosyl- and N-acetylgalactosaminyl-
transferases. Sulfation of the repeating disaccharides by the
4- and/or 6-sulfotransferases completes the synthesis of
mono- or disulfated CS (27) (see Fig. 11 for summary) .
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thesis was not affected by BFA, as shown by the incor-
poration of [6-3H]galactose into a protein-carbohydrate
linkage region that was sensitive to ß-elimination. The
ability of cells to use an exogenous acceptor, p-nitro
phenyl-ß-D-xyloside, to elongate and sulfate core pro-
tein-free glycosaminoglycans, was completely inhibited
by BFA. The effects of BFA were completely reversible
in the absence of new protein synthesis. These experi-
ments indicate that BFA effectively uncouples chondroi-
tin sulfate glycosaminoglycan synthesis by segregating
initiation reactions from elongation and sulfation events.
Our findings support the proposal that glycosaminogly-
can elongation and sulfation reactions are associated
with the trans-Golgi network, a BFA-resistant, Golgi
subcompartment.
It is generally accepted that GAG synthesis is a Golgicom-
plex-related event. Early studies using electron microscopy
and radioautography showed that the Golgi complex is the
major site of GAG chain synthesis (21, 24, 25). Golgi-en-
riched preparations isolated from some cell types have also
been shown to contain GAG synthesizing activity (32). More
recent studies examining the kinetics of entry ofradiolabeled
sugars into GAG chains, as well as the localization of GAG
sugar nucleotide and sulfate donor transport systems, have
clearly localized GAG synthesis to the Golgi complex (14,
18, 23). The exact spatial organization of the cascade of en-
zymatic reactions involved in GAG synthesis is not known,
due, in part, to the lack of understanding of the dynamics
and spatial differentiation of the Golgi complex.
The Golgi complex can be divided into at least four dis-
tinctregions, the cis-, medial, and trans-Golgi and the trans-
Golginetwork (TGN) (2, 5, 12, 13, 15) . The specific changes
induced by the fungal metabolite, brefeldin A (BFA), have
provided new information on how the structural organization
of the Golgi complex relates to function. BEN dramatically,
yet reversibly, alters Golgi morphology and function by dis-
rupting the budding ofnonclathrin-coated transport vesicles
responsible for anterograde movement (3, 22). The result is
a block in anterograde protein transport out of the ER (20)
and a redistributionofcis-,medial, and trams-Golgi-resident
enzymes back to the ER through a retrograde, microtubule-
dependent pathway (16, 17). In contrast, the compartmen-talization processes involved in the formation of the TGN,
lysosomes, and endocytic vesicles are resistant to the redis-
tribution induced by BFA (2, 20).
The aim of this study was to further define the dynamic
topology of GAG synthesis using BFA and the human
melanoma-associated proteoglycan (MPG) model system.
We demonstrate that BFA reversibly uncouples GAG chain
initiation from elongation and sulfation events. In the pres-
ence ofBFA, the MPG core protein is retained in the ER and
acquires complex N-linked oligosaccharides but is not con-
verted to a CS proteoglycan form. In addition, BFA-treated
cells fail to elongate and sulfate GAG chains onto the exoge-
nous, artificial GAG acceptor, p-nitrophenyl-ß-D-xyloside
(ODX) . Initiation of GAG synthesis in the presence of BFA
proceeds through to the addition of the xylosyl residue and
the galactosyl residues of the carbohydrate-protein linkage
region. These results indicate that GAG chainelongation and
sulfation are BFAresistant events which are associated with
the TGN.
Materials and Methods
Materials
BFA was obtained from Sandoz Pharmaceuticals (Basel, Switzerland).
Deoxymannojirimycin (DMJ) and endoglycosidase H (endo-ß-N-acetyl-
glucosaminidase) werepurchased fromBoehringer Mannheim Diagnostics,
Inc. (Indianapolis, IN) and Genzyme Corp. (Boston, MA). Sephadex G-25
PD-10columns and protein A-Sepharose C1-4B were purchased from Phar-
macia Fine Chemicals (Piscataway, NJ). [35S]Methionine (1,295 Ci/mmol),
[35S]sulfate (25-40 Ci/mg), [6-3H]galactose (25.5 Ci/mmol) and NaI'25
(15.8 mCi/tug) were obtained from Amersham Corp. (Arlington Heights, IL).
All reagents usedforcell surface iodination procedures (Enzymobeads) and
SDS-PAGE were purchased from Bio-Rod Laboratories (Richmond, CA).
Neuraminidase (Clostridiumperfringens or Vbriocholera), chondroitinase
ABC, chondroitin sulfateA and C carriers, ODX, FITC- and TRITC-conju-
gated wheat germ agglutinin (WGA) and anti-mouse immunoglobulin anti-
bodies were from Sigma Chemical Co. (St. Louis, MO). Cycloheximide
was purchased from Calbiochem-Behring Corp., San Diego, CA). The AX5
HPLC column was purchased from Varian Instruments (Palo Alto, CA).
O-Galactosidase (chicken liver) was purchased from Oxford Glycosystems
(Rosedale, New York). ["C]AcAsnMan6GlcNAc2 glycopeptide was pre-
pared as previously described (6). All other materials were reagent grade.
CellLinesand Treatment with Inhibitors
The M21 humanmelanoma cell line is a subclone, propagatedin ourlabora-
tory, ofthe UCLA-SO-M21 cell line provided by Dr. D. L. Morton (UCLA,
Los Angeles, CA) . TheUACC-903 human melanomacell line was provided
by Dr. J. M. Trent (University of Michigan, Ann Arbor, MI). The human
B-lymphoblastoidcell line, Raji, wasobtained from Dr. A. N. Theofilopou-
los (The Scripps Research Institute, La Jolla, CA). Cell lines were propa-
gated at 37°C in 5% C02 in RPMI 1640 or DME culture media supple-
mented with 10% FCS (Whittaker M.A. Bioproducts, Inc., Walkersville,
MD), 2 mM glutamine, and 50 tug/ml gentamicin sulfate (Sigma Chemical
Co.). A stock solution of BFA was made in methanol at a concentration of
2 mg/ml and stored at -20°C. Deoxymannojirimycin was made as a stock
solutionof 10 mg/ml inculturemedia. Cells were preincubated ininhibitors
for 1-6 h before analysis, depending upon the nature of the experiment, as
described in the figure legends. No significant loss of viability of cells re-
sulted fromany inhibitor treatment asjudged by trypanblue exclusion and/
or TCA-precipitable counts per minute of ["S]methionine incorporated
into protein.
Antibodies
The mAb 9.2.27 (IgG2a), directed against the MPG core protein was devel-
oped as described previously (1). The rabbit C351 antibody directed to
a COOH-terminal peptide sequence of the class II-associated invariant
chain was provided by Dr. Vito Quaranta (The Scripps Research Institute,
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La Jolla, CA) and was produced as described previously (10). Sera from
preimmunizedrabbits or fusionpartner culture supernatants servedasnega-
tive controls in all immunoprecipitation experiments.
Radiolabeling andImmunoprecipitationAnalysis
Metabolic radiolabeling, cell surface iodination, and immunoprecipitation
of specific antigens were performed as described previously (33, 34). 5-8
x 106 cells per sample were used in all experiments. Labeling with [6-
3H]galactose was carried out in low glucose culture media (DME, 1,000
mg glucose/liters or RPMI 1640, 0.1 mg glucose/ml) with 100 ACi/mI of
[3H]galactose for 4-6 h at 37°C. The choice of [6-3H]galactose is impor-
tant because it cannot be converted into [3H]glucuronic acid. Quantitation
of SDS-PAGE profiles was performed by densitometric scanning of au-
torads.
Quantitation ofProteoglycansand
ß-DXyloside-initiated GAGs
The quantitation of [35S]sulfate-labeled macromolecules was carried out as
previously described (33, 34).
Isolation ofPH]Galactose-labeled Molecules
Immunoprecipitates isolated with mAb 9.2.27 from [6-3H]galactose-
labeled cells were washed extensively in PBS containing Q5% Tween-20
and 1 mg/ml ovalbumin. [3H]galactose-labeled O-linked oligosaccharides
were then released from the MPG core protein by treatment with 20 tul of
0.05 N NaOH and 0.3 M NaBH4 overnight at room temperature. The
released chains wereneutralized with acetic acid and evaporated three times
in McOH/OHAc to remove borate salts. The sample was diluted to 1.5 ml
in 2-mM Tris base and passed over a 2-cm column of QAE-Sephadex
equilibrated in 2 mM Tris. Neutral species that ran through the column
(56% ofthe starting material) were desalted on a mixed bed ion exchange
resin (MB3) . Recovery was >90%.
HPLCAnalysis ofNeutralOligosaccharides
Neutral oligosaccharides were analyzed onan AX5 anion-exchangecolumn
using a 40-80% gradient of acetonitrile in 25 mM NaPO4, pH 6.5, in 30
min at a flow rate of 1 ml/min. Fractions of0.5 ml were counted. Each run
included an internal standard of "C-fucitol andan ovalbumin glycopeptide,
["C]AcAsnMan6GlcNAc2. 0-galactosidase digestions were carried out in
50 Al of 100-mM citrate-P04 buffer at pH 4.5 for 16 h at 37°C using 0.05
U of enzyme.
Immunofluorescence Microscopy
M21 cells were grown on 12-mm round glass coverslips placed in 24-well
culture dishes andpretreated with BFA for 1 h at 37°C. The coverslips were
then washed in ice-cold PBS/0.1% BSA and fixed immediately in a 3%
paraformaldehyde solution in 0.1 M sodium phosphate, pH 7.4, for 15 min
on ice. The coverslips were then washed in PBS followed by 0.1 M glycine.
Cell surface immunofluorescence was blockedbeforepermeabilization with
a human/mouse chimeric form ofmAb 9.2.27, containing human heavy and
light chain constant regions (11), and withWGA for 30 minat room temper-
ature. The fixed and blocked cells were then permeabilized in0.15 % sapo-
nin in PBS/0.1% BSA for 15 min and incubated with primary antibody for
1 hat room temperature. After washing, the coverslips were incubated with
fluorescently labeled anti-mouse secondary antibody or WGA for 1 h at
room temperature, washed and mounted on glass slides in Fluoromount G
(Southern Biotechnology Assoc., Birmingham, AL). Mounted slides were
viewed with a IOOX oil Neofluor lens on a microscope (both from Carl
Zeiss, Inc., Thornwood, NY) equipped with barrier filters to prevent cross-
over of fluorescein and rhodamine fluorescence.
Results
BFA Inhibits CS GAG Chain Elongation and
Sulfation on theMPG CoreProtein
The human melanoma MPG antigen recognized by mAb
9.2.27 is synthesized initially as a240ÁD precursorthat con-
1464Figure 1 . Effect ofBFAon the synthesis and assembly of the MPG.
M21 cells were pretreated with the indicated concentrations ofBFA
for 1 h before a 4-h label with P5S]methionine at 37°C in the pres-
ence ofdrug . The MPG complex was then isolated from detergent
lysates of cells by immunoprecipitation with mAb 9.2.27 and was
subjected to SDS-PAGE (5% gel) and autoradiography . A dose-
dependent inhibition of the conversion of the 240-kD form to the
250-kD and proteoglycan form (PG) is observed in the presence
of BFA. Molecular mass standards are in kilodaltons .
tains N-linked oligosaccharides of the high mannose, endo
H-sensitive type. Trimming and processing of the N-linked
oligosaccharides to the complex, endo H-resistant, and si-
alylated form results inthe conversion of the 240-kD compo-
nent to a 250-kD form . The addition of GAG chains to the
250-kD core protein converts it to a high molecular mass
(>450 kD) proteoglycan form (1, 33, 34) . The composition
oftheMPGGAGS has been previously shown to be the 4-sul-
fated form of chondroitin sulfate with a molecular mass be-
tween 20 and 60 kD (9, 33) .
Treatment ofM21 human melanoma cells with increasing
concentrations ofBFA results in a dose-dependent inhibition
of the conversion ofMPG core protein to itsCS proteoglycan
form (Fig . 1) . Inhibition becomes apparent between 16-32
ng/ml and is complete at higher concentrations . There is no
effect on protein synthesis or viability under these labeling
conditions at concentrations up to 50 ug/ml (data not shown) .
An intermediate form of the core protein accumulates along
with the 240-kD species in the presence ofBFA . At higher
concentrations ofBFA all of the core protein is converted to
the 240-kD form (Fig . 1) . No high molecular mass form or
chondroitinase ABC-sensitive form (data not shown) of the
MPG is observed in the presence ofBFA, suggesting an inhi-
bition ofCS GAG chain elongation . The complete inhibition
of incorporation of [ 35S]sulfate into the MPG complex is
also consistent with an absence of GAG chain elongation
and sulfation (Fig . 2, left panel) . Identical results were ob-
tained in three additional human melanoma cell lines (data
not shown) .
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Figure2. BFA inhibits sulfation, cell surface expression and release
ofthe MPG. M21 cells were pretreated in the presence or absence
ofBFA (1 pg/ml) for 1 h before a 3-h label with either [35S]sulfate
(left panel) or [35S]methionine (right panel) at 37°C in the pres-
ence and absence ofthe drug. TheMPG complex was then isolated
from either detergent cell lysates or dialyzed spent media by immu-
noprecipitation with mAb 9.2.27. Cell surface analysis (middle
panel) was performed on M21 cells harvested by trypsin treatment
to remove the cell surface MPG component . Harvested cells were
incubated in suspension for 4 h at 37°C in the presence or absence
ofBFA (1 ug/ml) to allow recovery of the cell surface MPG. Cell
surface iodination was then performed as previously described (33)
and MPG complexes were isolated from detergent lysates of cells
with mAb 9.2 .27. All samples were then subjected to SDS-PAGE
(5 % gel) . No forms of the MPG complex are observed in [ 35S]sul-
fate-, cell-surface-, or spent media-labeled samples prepared inthe
presence ofBFA. Molecular mass standards are in kilodaltons . PG
designates the proteoglycan form of the MPG .
BFA BlocksMPG Core Protein Transport out
oftheER
The complete transport and assembly of the MPG complex
results in the expression of both the 250-kD and proteogly-
can components on the cell surface (33, 34) . Truncated
forms of both these species are also released into the culture
media (Spiro, R ., unpublished observation) . MPG forms
could not be isolated from either 1251 cell surface-labeled
M21 cells that were trypsinized and pretreated with BFA or
from the [35S]methionine-labeled culture media of such
cells (Fig . 2, middle and rightpanels) . The absence ofMPG
cell surface expression and release is consistent with an ar-
rest in intracellular transport of the core protein . To deter-
mine the subcellular site of the arrest, the distribution of the
MPG core protein in the presence of BFA was examined by
immunofluorescence microscopy with mAb 9.2 .27.
TheMPG complex shows a localized perinuclear staining
pattern in fixed and permeabilized M21 cells when stained
withmAb 9.2 .27 and a FITC-conjugated secondary antibody
(Fig . 3 A) . This staining pattern is typical ofthe Golgi com-
plex as confirmed by the co-localization of the TRITC-
1465Figure 3. BFA blocksMPG transport at the ER level . M21 cells were treated without (A and B) or with (C and D) 1 Pg/ml BFA for 1 h
before fixation, blocking, and permeabilization as described in Materials and Methods . Cells were then incubated with mAb 9.2.27 and
fluorescently labeled secondary antibody (A and C) or with fluorescently labeled wheat germ agglutinin (B andD) . A and C were pho-
tographed with fluorescein optics and B and D with rhodamine optics . BFA causes a morphologic redistribution of the Golgi complex .
The MPG core protein shows an ER-like distribution in the presence of BFA . Bar, 10 gym .
conjugated distal Golgi stack marker, WGA (Fig. 3 B) . In
contrast, treatment of the cells withBFA before fixation and
permeabilization results in a more diffuse, reticular 9.2.27
staining pattern that is typical of the ER (Fig . 3 C) . The
golgi-specific WGA staining also becomes more diffuse,
consistent with a BFAinduced morphologic Golgi redistri-
bution (Fig . 3 D) (16) . These results suggest that the trans-
port of theMPG core protein is blocked between theER and
the Golgi in the presence of BFA .
TheMPGN-linked Oligosaccharides AreProcessed in
BFA-treated Cells
The BFA-induced effects on the Golgi complex have been
previously shown to cause a redistribution of cis-, medial,
and trans-Golgi-resident enzymes back to theER (2, 16, 17) .
To examine if Golgi enzymes are redistributed in BFA-
treated melanoma cells, the processing oftheMPG core pro-
tein N-linked oligosaccharides was monitored by endo H
digestion of MPG immunoprecipitates isolated from M21
cells pretreated, pulse labeled, and chased in the presence
ofBFA . Immediately after the pulse label, the 240-kD form
oftheMPG is susceptible to endoH digestion in both control
and BFA-treated cells. After 15-30 min, and throughout the
remainder of the chase period in control cells, the 240-kD
precursor is converted to the 250-kD, endo H-resistant form
and the high molecular massCS proteoglycan (Fig . 4 A) (33,
34) . In BFA-treated cells, the 240-kD form gradually ac-
quires endo H resistance during the chase period and be-
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comes completely resistant by 9 h . This acquisition of endo
H resistance is accompanied by a slight increase in molecu-
lar mass, but complete conversion to the 250-kD or the pro-
teoglycan form is inhibited by BFA (Fig . 4 a) . Neuramini-
dase digestion of the MPG isolated from cells labeled with
[e 5S]methionine for 1 h and chased for 3 h in the presence
ofBFA results in a shift in mobility of the core protein, indi-
cating the acquisition ofsialic acid residues (Fig . 4 b) . These
results are consistent with the recycling, back to the ER, of
the Golgi resident enzymes that trim and terminally process
the N-linked oligosaccharides ofthe ERretainedMPG core
protein . The absence of the proteoglycan form of the MPG
suggests that the redistribution ofCS GAG enzymes to the
ER does not occur or that their redistribution results in a loss
of functional activity.
BFA Does NotBlockInitiation ofCSGAGSynthesis
on theMPG Core Protein
The extent of CS GAG chain initiation occurring in the
presence of BFA was evaluated by metabolically labeling
the carbohydrate-protein initiation linkage region (Ser-Xyl-
Gal-Gal-G1cUA) with [6-3H]galactose . Pretreatment of
cells with DMJ was used to inhibit the labeling of complex
N-linked oligosaccharides, thereby limiting the incorpora-
tion of [3H]galactose exclusively to O-linked oligosaccha-
rides. DMJ has previously been shown to block the process-
ing ofthe MPG core protein N-linked oligosaccharides at the
high mannose stage without effecting conversion to the pro-
1466teoglycan form (34) (Fig . 5, left side) . In control M21 cells
labeled with [3H]galactose, label is incorporated into both
the 250-kD and proteoglycan forms of the MPG complex
(Fig . 5, right side) . In cells pretreated with DMJ, incorpora-
tion into the core protein form is blocked by 97 %, but is only
partially reduced in the proteoglycan form . Cells pretreated
with BFA also incorporate ['H]galactose into the MPG core
protein, even in the presence of DMJ (Fig . 5, right side) .
This result is consistent with the addition ofthe xylosyl resi-
due and at least one of the galactosyl residues of the GAG
carbohydrate-protein linkage region in the presence ofBFA .
To precisely determine the effects ofBFA on the synthesis
of the carbohydrate-protein linkage region, the [3H]galac-
tose-labeled sugar chains were released from the MPG core
protein by ß-elimination and their size and charge were ana-
lyzed by HPLC and QAE-Sephadex ion exchange chroma-
tography, respectively. About 56% ofthe released chains are
neutral, and two peaks are seen in HPLC analysis (Fig. 6) .
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Figure 4. N-linked oligosaccharides ofthe MPG core protein are processed in the presence ofBFA .
(A) M21 cells were pretreated for 1 h with or withoutBFA (10 pg/ml ; identical results obtained with
1 ug/ml) before a 10-min pulse label with [35S]methionine . Cells were then washed and chased in
unlabeled media in the presence or absence of BFA . At the indicated time points, aliquots of cells
were lysed in detergent andMPG complexes were isolated by immunoprecipitation withmAb 9.2.27.
Immunoprecipitates were digested or mock digested with endoH (Endo R) for 1 h at 37°C and were
then subjected to SDS-PAGE (5 % gel) and autoradiography. The MPG core protein gradually ac-
quires endo H resistance but is not converted to the 250-kD or the proteoglycan form (PG) in the
presence ofBFA . (B) M21 cells were pretreated for 30 min with or without BFA (1 jig/nil) before
a 1-h pulse label with [35S]methionine and a 3-h chase with or without BFA . MPG immunoprecipi-
tates were isolated from detergent lysates of cells with mAb 9.2.27 and were digested or mock
digested with neuraminidase for 2 h at 37°C before SDS-PAGE analysis on a 3-5% gradient gel .
The shift in migration of the BFA-treated MPG core protein after neuraminidase (Neur) digestion
indicates the acquisition of sialic acid residues . Molecular mass standards are in kilodaltons . PG
designates the proteoglycan form of the MPG.
ß-galactosidase digestion eliminates both peaks and gen-
erates a monosaccharide peak, presumably free [3H]galac-
tose, which elutes slightly later than the '°C-fUcitol stan-
dard, as expected (7) . The major peak is probably the linkage
region, Xy1H 01-4-Gal 01-3-Gal, and the minor peak is
probably Xy1H ßl-4-Gal . Chromatography on QAE-Sepha-
dex showed that 43% of the labeled material carries one to
three negative charges, based on comparison with appropri-
ate standards (data not shown) . The characterization and
identity ofthis material will be reported elsewhere . These re-
sults suggest that the BFA-induced block in the MPG GAG
chain elongation and sulfation is not due to a complete block
in the initiation events.
BFA-treated Cells Fail to Synthesize GAGChains onto
Xyloside Acceptors
To evaluate the activity ofthe GAG chainenzyme machinery
1467Figure 5. BFA does not block the initiation of CS GAG synthesis .
M21 cells were pretreated for 1 h with or without BFA (1 pg/nil)
or deoxymannojirimycin (DMJ) (10 mM) for 1 h before a 4-h label
with [35S]methionine or [6-3H]galactose at 37°C. MPG immuno-
precipitates were isolated from detergent lysates with mAb 9.2.27
and subjected to SDS-PAGE (5% gel) and autoradiography. BFA
does not block the incorporation of [ 3H]galactose into the MPG
core protein under conditions (+ DMJ) where incorporation is re-
stricted to the CS GAG initiation linkage region . Molecular mass
standards are in kilodaltons . PG designates the proteoglycan form
of the MPG .
in the presence ofBFA, independent of the MPG core pro-
tein, treated cells were tested for their ability to elongate and
sulfate GAG chains onto the exogenous acceptor, ßDX . As
an artificial GAG acceptor, ßDX diffuses freely into cells to
the sites ofGAG synthesis where it substitutes for the xylose
residue of the initiation linkage region and allows polymer-
ization and sulfation ofGAGs onto itself. The smaller ODX-
boundGAGs are then efficiently exocytosed into the culture
media (30) . Since initiation and elongation are prerequisites
for sulfation, the integrity of the GAG chain enzyme ma-
chinery can be evaluated, independent ofcore protein struc-
tures, by monitoring the increase in incorporation of ['IS]-
sulfate into macromolecules in the presence of ßDX .
In a representative experiment, incubation of M21 cells
with 1mM ßDX results in a 10-fold increase in the mean in-
Figure 6. HPLC analysis
of neutral [6- 3H]galactose-
labeled base/borohydride-re-
leased sugar chains . Desalted
sugar chains were mixed with
'4C-fucitol and h4C]AcAsn-
Man6GlcNAC Z oval-bumin gly-
copeptide and applied to a
Varian AX5 column and eluted
with a linear gradient of 40
80% acetonitrile in 25 mM NaPO4 buffer as described in Materials
and Methods either before (o) or after (e) digestion with 0-galac-
tosidase. Standards : 1,[ 14C]-fucitol ; 2, [3H]Gal-Ga1NAcitol. The
glycopeptide standard elutes at fraction 80 and is not shown .
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corporation of [35S]sulfate into 31S-macromolecules (33, 34)
(Fig. 7) . The proportion of 31S-macromolecules released
into the culture media increases from 40 to 79% in the pres-
ence of ßDX, representative of the exocytosis of the free,
ßDX-initiated, GAG chains . In contrast, pretreatment of the
cells with BFA results in a dose-dependent inhibition of in-
corporation of sulfate into ßDX-initiated macromolecules .
The observed inhibition is not due to a block in the uptake
of ßDX since identical results are obtained in cells that are
preloaded before BFA treatment (data not shown) . At 20
ng/nll ofBFA, incorporation of [3IS]sulfate is only 59% of
control cells, and at higher concentrations (0.2 and 2 pg/ml)
the inhibition is virtually complete with incorporation di-
minishing to 1% of control cells (Fig . 7) . Similar experi-
ments performed with [6-3H]galactose demonstrated the
accumulation of [3H]galactose intermediates linked to ßDX
(data not shown) . The dose response range demonstrated
here correlates well with that observed in Fig . 1 for inhibi-
tion ofconversion of theMPG core protein to the proteogly-
can form . These results indicate that BFA completely dis-
rupts the ability of cells to use an exogenous, artificial
acceptor for the elongation and sulfation ofGAG chains . To
determine if BFA permanently damages the GAG enzyme
machinery, the reversibility of its effects was tested in the ab-
sence and presence of new protein synthesis .
Reversibility ofBFA E ffects
The effects ofBFA on the synthesis ofthe MPG proteoglycan
form are completely reversible. In M21 cells pretreated with
BFA for 30 min, pulse-labeled for 10 min, and then washed
and chased in the absence of BFA, conversion of the MPG
core protein to the proteoglycan form begins between 1 and
2 h of release fromBFA (Fig. 8) . After an overnight release,
both the 250-kD andCS proteoglycan forms can be isolated
from the BFA-treated cells, as demonstrated by chondroi-
tinaseABC digestion ofthe immunoprecipitates before SDS-
PAGE analysis (in Fig . 8, 24 hour time point) . Interestingly,
after recovery from BFA treatment, a higher proportion of
the MPG is expressed as the 250-kD rather than the proteo-
glycan form . This indicates that not all of the core protein
that accumulates in the presence of BFA can serve as sub-
strate for chondroitin sulfate synthesis after removal of the
drug . The reversibility of the BFA-induced effects does not
require new protein synthesis . Identical results are obtained
in cells treated with BFA and released under conditions
where protein synthesis is inhibited>90% by cycloheximide
(data not shown) .
The effects of BFA on the ability ofM21 cells to use the
exogenous ßDX acceptor are also completely reversible .
Cells pretreated withBFA and then released in drug-free me-
dia for 2 h incorporate [31S]sulfate into ßDX-initiated GAG
chains at levels equal to control cells . Identical results are
obtained in cells released in the presence of cycloheximide
(Fig . 9) . The reversibility in the absence ofnew protein syn-
thesis indicates that the GAG elongation and sulfation en-
zymes are present, but inactive, in BFAtreated cells .
BFA Inhibits the Conversion ofthe Class II-associated
InvariantChain to a ProteoglycanForm
To address the generality of the BFA-induced inhibition of
GAG chain synthesis, the effects on the conversion ofthe ma-
1468Figure 7 . BFA inhibits )3-D-xyloside-initiated
GAG synthesis. M21 cells were pretreated for
1 hwith or without BFA (1 pg/ml) andp-nitro-
phenyl-ß-D-xyloside (1 mM) for 15 min before
a 1 h label with [35S]sulfate in the presence or
absence of BFA. Cell-associated (hatched re-
gion) or exocytosed (nonhatched region) 35S-la-
beled macromolecules were quantitated after
their exclusionfrom Sephadex G-25 under dis-
sociative conditions as described (33, 34) . The
height of the bar indicates total [35S]sulfate in-
corporation . The percent of total [35S]sulfate
incorporation into control cells is indicated at
the top of each bar. A dose-dependent inhibi-
tion ofthe ability ofcells to elongate and sulfate
GAGs onto an exogenous acceptor is observed
in the presence ofBFA. Data are expressed as
the mean of duplicate cultures with the range
of values indicated .
Figure 8. The effects of BFA on assembly of the MPG are reversible . M21 cells were pretreated for 1 h with or without BFA (1 pg/ml)
before a 10-min pulse with [35S]methionine at 37°C . The cells were then washed and chased in unlabeled media in the absence ofBFA.
At the indicated time points, an aliquot ofcellswas harvestedandMPGimmunoprecipitates were isolated from detergent cell lysates with
mAb 9.2.27. Digestion or mock digestion of immunoprecipitates with either endo H (EndoH) or chondroitinase ABC (CaseABC) was
performed for 1 h at 37°C before being subjected to SDS-PAGE (5% gel) and autoradiography. Conversion of the MPG core protein to
the proteoglycan form (PG) begins to appear after 1-2 h of release from BFA treatment . Molecular mass standards are in kilodaltons .
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Discussion
Control
1.5 h treatment
jor histocompatibility complex class R-associated invariant
chain were examined in the Raji B-lymphoblastoid cell line .
The invariant chain consists of a family of 31-41-kD glyco-
proteins that are associated with the class II « and (3 subunits .
The invariant chain is also converted to a CS proteoglycan
form that can only be identified in ["S]sulfate-labeled cells
(10, 29) . Treatment of Raji cells with BFA completely blocks
the conversion of the invariant chain to a proteoglycan, as
judged by the inhibition of [35S]sulfate incorporation into
this form (Fig . 10, right panel) . The increase in resistance
to endo H digestion of the [35S]methionine-labeled invari-
ant chain forms demonstrates the acquisition of complex
N-linked oligosaccharides in the presence ofBFA (Fig . 10,
left panel) . Therefore, the effects ofBFA on GAG chain syn-
thesis are not restricted to melanoma cells and are not a
peculiarity of the MPG system .
The current model for the posttranslational addition ofGAG
chains proposes that synthesis and maturation occur during
the intracellular vesicular transport of core proteins from the
ER through the Golgi complex (18, 27) . This assembly pro-
cess requires the precise coordination oftemporal and spatial
parameters that can influence core protein access to initia-
tion, elongation, and sulfation enzymes . Previous studies
have shown that agents which disrupt vesicular transport, or
inhibit core protein release from the ER, also inhibit GAG
chainaddition to theMPG core protein with little or no effect
on ODX-dependentGAG synthesis (33, 34) . However, the in-
terpretation of these previous results is restricted by the
limited data on the effects of these agents on the structural
and functional integrity of the vesicular pathway and as-
sociated organelles . The well-defined effects of BFA now
make it possible to further delineate the topology of the CS
GAG enzymatic machinery.
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Figure 9 The effects of BFA on ODX-
initiated GAG synthesis are reversi-
ble . M21 cells were pretreated for
0.5 h with or withoutBFA (1 Wg/ml)
and /3DX (1 rnM) before a 1-h label
with [35S]sulfate . One aliquot of
cells (1.5 h treatment) was then har-
vested and cell-associated (hatched
region) or exocytosed (nonhatched
region) 35S-macromolecules were
quantitated as described in Figure 6.
A second aliquot ofcells (2 h release)
was washed and chased for 1 h inme-
dia without BFA and in the absence
or presence of cycloheximide (100
jig/ml) before addition of the (ODX
and the 1-h label with [35S]sulfate .
The height of the bar indicates total
[ 35S]sulfate incorporation . Complete
recovery from BFA treatment is ob-
served within2 h ofrelease in the ab-
sence ofnew protein synthesis . Data
are expressed as the mean of dupli
i
￿
cate cultures with the range ofvalues
indicated .
The results presented in this study demonstrate that the
Golgi-specific changes induced by BFA have a profound
effect on CS GAG synthesis . BFA caused a dose-dependent,
yet completely reversible inhibition of CS GAG elongation
and sulfation onto the MPG and invariant chain core pro-
teins, as well as onto the exogenous, artificial GAG acceptor,
ODX . BFA did not affect the initiation ofCSGAG synthesis,
including addition of the xylosyl residue and the galactosyl
residues ofthe initiation linkage region . The simplest expla-
nation for these findings is thatCSGAG chain elongation and
sulfation enzymes are resistant or insensitive to the redistri-
bution induced by BFA, while the initiation enzymes are not
(Fig . 11) . This results in the complete uncoupling ofCS GAG
chain initiation from the elongation and sulfation events in
a manner completely analagous to the BFAinduced un-
coupling of glycosphingolipid synthesis (39, 40) .
The strongest line of evidence supporting the idea that
BFA uncouples CS GAG synthesis comes from the experi-
ment that demonstrates GAG initiation, in the absence of
elongation and sulfation, by analyzing the incorporation
of ['H]galactose into the carbohydrate-protein linkage re-
gion . Under conditions where incorporation was restricted
to 0-linked oligosaccharides, by treatment with DMJ, label
was incorporated into the MPG core protein that accumu-
lated in the presence ofBFA (Fig . 5) . SinceGAG chains rep-
resent the majority of, if not the only, 0-linked oligosaccha-
rides of the MPG complex (9, 28), the incorporation of
[3H]galactose into the BFA-treated core protein is consis-
tent with the addition of the xylosyl residue and the galac-
tosyl residues of the initiation linkage region . Results from
the fine structure analysis indicated that the [ 3H]galactose is
predominately (56%) incorporated into neutral species that
are sensitive to ,8-galactosidase digestion and probably rep-
resent the linkage region (Fig . 6) . A portion (43%) of thema-
terial is anionic and its identity will be reported elsewhere.
The complete inhibition of /ODX-dependent CS GAG chain
1470Figure 10 . BFA inhibits addition of GAG chains onto the class 11
invariant chain . Raji, B-lymphoblastoid cells were pretreated with
and withoutBFA (1 ttg/ml) for 1 h before a 6-h label with [35S]me-
thionine or ["S]sulfate in the presence or absence of BFA . The
class 11-associated invariant chain was then immunoprecipitated
from detergent lysates of cells with the C351 antibody and was
digested or mock digested with endoH (Endo H) before SDS-PAGE
(10% gel) and autoradiography. BFA completely blocks the conver-
sion of the invariant chain to a high molecular mass, sulfated pro-
teoglycan form. The glycoprotein forms acquire increased resis-
tance to endoH digestion in the presence ofBFA . Molecular mass
standards are in kilodaltons .
polymerization and sulfation induced byBFA is also consis-
tent with an uncoupling ofGAG synthesis . As a xylose ana-
logue, ßDX diffuses freely into the cell to substitute for the
normal carbohydrate-protein linkage residue (30) . The an-
terograde intracellular transport ofßDX molecules through
the Golgi complex results in the formation of core protein
freeGAG chains that are efficiently exocytosed from the cell .
In the presence ofBFA, theßDX molecules that diffuse into
the ER become properly initiated due to the redistribution
of enzymes from BFA-sensitive compartments . The initiated
molecules do not, however, gain access to the elongation and
sulfation enzymes in BFA-resistant compartments because of
the BFAinduced block in anterograde vesicular transport .
Similarly, the ßDX molecules that initially diffuse to the
BFA-resistant compartments do not become properly initi-
ated to serve as substrates for elongation and sulfation . This
results in the complete inhibition of ßDX-dependent CS
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GAG synthesis . Upon removal of BFA, transport between
BFA-sensitive and resistant compartments is reestablished
andßDX-initiated CSGAG synthesisquickly recovers within
1 h . The complete recovery in the absence ofnew protein
synthesis is further proofthat the elongation and sulfationen-
zymes are present but segregated from the initiation enzymes
in BFA-treated cells .
There are other possible explanations for the inhibition of
CS GAG synthesis induced by BFA, including the direct inhi-
bition of the elongation and sulfation enzymes or the absence
of redistribution of the proper nucleotide sugar and sulfate
donor transport systems . Either mechanism would result in
the observed inhibition ofCS GAG synthesis, regardless of
the location ofthe elongation and sulfation enzymes after the
BFA-induced redistribution . However, results from previous
studies argue against these possibilities . BFA does not inhibit
the in vitro activity of several glycosyltransferases and does
notaffect the uptake of UDP-sugars (20, 36) . In addition, the
sialylation of the MPG core protein in the presence ofBFA
demonstrates that the Golgi-resident CMP-sialic acid trans-
port system (14, 23) and some sialytransferase can be re-
distributed to the ER . The recent data demonstrating that
BFA causes the disruption of a Golgi-specific structural pro-
tein suggests that its mode of action is directed towards the
structural integrity of the Golgi rather than the resident en-
zymes (3, 22) . For these reasons it is more likely that the
BFA-induced inhibition ofCS GAG synthesis is due to the
segregation of initiation and elongation-sulfation enzymes
intoBFAsensitive and -resistant compartments, respectively
(Fig. 11) .
The results presented here strongly support the proposal
that CS GAG chain elongation and sulfation are TGN-
associated events . This follows directly from the results of
Chege and Pfeffer (2) who showed that the TGN is a BFA-
resistant, Golgi sub-compartment . The localization of CS
elongation and sulfation events to the TGN extends the list
of TGN-resident enzymes to include the specific glycosyl-
and sulfotransferases involved in these reactions. It has been
previouslyshown that some classes of sialyltransferases and
the GA2/GM2/GD2 synthase are localized in a BFA-resis-
tant compartment (2, 31, 38-40) . Further structural studies
on the specific enzymes involved in these reactions will help
to determine the mechanism responsible for their specific
targeting to the TGN .
The mapping of CS GAG elongation and sulfation to the
TGN is completely consistent with previous kinetic studies
ofGAG synthesis (18, 19, 35) . While the exact site ofthe ini-
tial xylosylation reaction has been debated, it is generally
agreed that elongation and sulfation are later Golgi events .
The results presented here do not distinguish between anER
or early Golgi site for GAG initiation, but clearly segregate
it from GAG elongation and sulfation . It will be important
to determine whether a similar topology exists for the syn-
thesis of other classes of GAGS .
The TGN differs from the cis-medial, and trans-Golgi in
that it functions to sort proteins into transport vesicles that
are bound for distinct organelles or domains of the cell sur-
face (2, 4, 8, 26, 37) . It is interesting to speculate that the
addition ofa GAG side chain might influence the packaging
of core proteins into distinct transport vesicles bound for
different regions ofthe cell . The expression of core proteins,
147 1such as the MPG and invariant chain, in both glycoprotein
and proteoglycan forms, may ultimately reflect distinct sub-
cellular localization and/or function .
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